Wall Street rallies behind Lexeo Therapeutics (LXEO)’s gene therapy pipeline
I'm PortAI, I can summarize articles.
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is considered one of the best stocks to buy for quick gains. As of December 24, all eleven analysts covering the stock have given it a consensus buy rating. The target price ranges from $12 to $30, with a median price target of $19, indicating significant upside potential.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments